These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21040805)

  • 41. Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy.
    Chaplin DJ; Acker BD; Horsman MR
    Biomed Biochim Acta; 1989; 48(2-3):S264-8. PubMed ID: 2730621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
    Dalal S; Burchill SA
    Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
    Hill SA; Chaplin DJ; Lewis G; Tozer GM
    Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
    Murata R; Overgaard J; Horsman MR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1018-24. PubMed ID: 11704326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.
    Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED
    Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancement of vascular targeting by inhibitors of nitric oxide synthase.
    Davis PD; Tozer GM; Naylor MA; Thomson P; Lewis G; Hill SA
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1532-6. PubMed ID: 12459382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
    Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
    Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
    Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
    Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation.
    Shibata MA; Akao Y; Shibata E; Nozawa Y; Ito T; Mishima S; Morimoto J; Otsuki Y
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):681-91. PubMed ID: 17256131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combretastatin A-4 vascular damage to tumours.
    O'Brien C
    Mol Med Today; 1997 Sep; 3(9):369. PubMed ID: 9302685
    [No Abstract]   [Full Text] [Related]  

  • 52. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
    Salmon BA; Salmon HW; Siemann DW
    Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.
    Ley CD; Horsman MR; Kristjansen PE
    Neoplasia; 2007 Feb; 9(2):108-12. PubMed ID: 17356706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice.
    El-Emir E; Boxer GM; Petrie IA; Boden RW; Dearling JL; Begent RH; Pedley RB
    Eur J Cancer; 2005 Mar; 41(5):799-806. PubMed ID: 15763657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
    Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
    Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
    Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
    Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
    Chaplin DJ; Pettit GR; Hill SA
    Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
    Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
    Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.